This article reviews the current status, pivotal clinical trials, challenges, and future directions of GP IIb/IIIa blockade in the management of coronary artery disease.
Answers are grounded in this paper and cite their sources.
GP IIb/IIIa blockade retains niche relevance in high-risk CAD; this review leaves open optimal patient selection and integration with contemporary therapies.
T he importance of thrombosis in the pathogenesis of acute coronary syndromes is now unequivocally established.1,2 These syndromes (unstable angina, nonϪQ-wave myocardial infarction [MI], acute [ST-elevation] MI, and abrupt closure after coronary intervention) share a common pathophysiology of atherosclerotic plaque rupture, activation of the coagulation cascade, and adhesion, activation, and aggregation of platelets.Numerous investigators have shown that the glycoprotein IIb/IIIa (GP IIb/IIIa) integrin mediates the "final common pathway" in platelet aggregation, spawning the development of GP IIb/IIIa receptor antagonists.[3][4][5] This article reviews the current status of GP IIb/IIIa blockade in the management of coronary artery disease, examining the results of pivotal clinical trials and reviewing current challenges and directions for future investigation.
No takes yet. Share an insight, caveat, or question.
Madan et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: